Deoxycholic Acid Promotes Persistent Low‐Level Viremia in Chronic Hepatitis B via Enhancing HBV Particle Formation
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Qiqi Ning und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B virus, Deoxycholic Acid, Viremia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Capital Medical University, Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes.
Abstract (Originalsprache)
Background
Low‐level viremia (LLV) during antiviral therapy predicts poor outcomes in chronic hepatitis B (CHB). Although bile acids (BAs) regulate HBV transcription, their role in LLV remains unclear. This study aimed to determine whether specific BAs affect antiviral efficacy and to identify potential therapeutic targets.
Methods
We analyzed 111 CHB patients, including LLV and lower detection limit (LDL) groups. Serum BAs were profiled by mass spectrometry. Propensity score matching (PSM), correlation, and ROC analyses evaluated the association between BAs and HBV DNA. In vitro, deoxycholic acid (DCA) was tested in HBV‐producing HepG2.2.15 and HBV‐infected HepG2‐NTCP cells. In vivo, HBV‐transgenic (HBV‐Tg) mice were used to assess hepatic DCA and HBV DNA correlation. Treatments included entecavir (ETV), antibiotics, and DCA supplementation. Molecular docking and mutagenesis were conducted to explore DCA–HBV surface protein (HBs) interactions.
Results
After PSM, LLV patients had elevated DCA, LCA, and TUDCA levels, which correlated with HBV DNA. DCA modestly predicted LLV by ROC analysis. In vitro, DCA promoted HBV Dane particle secretion and infection without altering viral protein expression. In HBV‐Tg mice, hepatic DCA correlated positively with HBV DNA. ETV and antibiotics reduced DCA and HBV DNA, whereas DCA supplementation reversed these effects. Mechanistically, DCA bound to LXXLL motifs in the HBs transmembrane domains, particularly TM2. TM2 mutations disrupted DCA binding, HBs–HBc interaction, and Dane particle formation.
Conclusion
Elevated DCA promotes viral persistence by enhancing Dane particle formation and stabilizing HBs‐HBc interactions, contributing to LLV during treatment. Modulating BA metabolism may offer new strategies to improve CHB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
- Beijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, China.
ORCID-Profile: Yuxue Gao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Capital Medical University
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes
- Scientific Research Project of Beijing Youan Hospital
Zitieren
APA
Ning, Q., Yang, P., Guan, Y., Cai, Y., Chen, D., & Gao, Y. (2025). Deoxycholic Acid Promotes Persistent Low‐Level Viremia in Chronic Hepatitis B via Enhancing HBV Particle Formation. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70090
Vancouver
Ning Q, Yang P, Guan Y, Cai Y, Chen D, Gao Y. Deoxycholic Acid Promotes Persistent Low‐Level Viremia in Chronic Hepatitis B via Enhancing HBV Particle Formation. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70090
BibTeX
@article{Ning2025,
author = {Ning, Qiqi and Yang, Pengxiang and Guan, Yuanyue and Cai, Yuying and Chen, Dexi and Gao, Yuxue},
title = {Deoxycholic Acid Promotes Persistent Low‐Level Viremia in Chronic Hepatitis B via Enhancing HBV Particle Formation},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.70090}
}
EUVIMED